Combination of oncolytic virus with immune checkpoint modulators
AssigneesInstitut Gustave Roussy, Transgene S.A.
InventorsLaurence Zitvogel, Xavier Preville, Laetitia Fend
Life of this patent
Estimating the term…
Abstract
The present invention provides a combination comprising at least an oncolytic virus and one or more immune check-point modulator(s) for use for the treatment of a proliferative disease such as cancer. It also relates to a kit comprising said oncolytic virus and said one or more immune checkpoint modulator(s) in separate containers. It also concerns a pharmaceutical composition comprising effective amount of said oncolytic virus and said one or more immune checkpoint modulator(s).
Claims12
A method of therapy in a human subject diagnosed with cancer, comprising administering to the human subject:
- i) an oncolytic vaccinia virus, wherein said oncolytic vaccinia virus is defective for thymidine kinase (TK) resulting from inactivating mutations in the J2R viral gene and defective for ribonucleotide reductase (RR) activity resulting from inactivating mutations in the viral 14L and/or F4L gene(s);
- and
- ii) a monoclonal antibody that specifically binds to CTLA-4 that is ipilimumab or tremelimumab;
- wherein i) and ii) are administered sequentially and i) is administered first and ii) second;
- wherein said oncolytic vaccinia virus is administered at a dose of 107 pfu to 5×109 pfu;
- and
- wherein said monoclonal antibody that specifically binds to CTLA-4 is administered at a dose of 2 mg/kg to 15 mg/kg.
A kit comprising:
- i) an oncolytic vaccinia virus in one container, wherein said oncolytic vaccinia virus is defective for thymidine kinase (TK) resulting from inactivating mutations in the J2R viral gene and defective for ribonucleotide reductase (RR) activity resulting from inactivating mutations in the viral 14L and/or F4L gene(s);
- and
- ii) a monoclonal antibody that specifically binds to CTLA-4 that is ipilimumab or tremelimumab in another container,
- wherein i) are intended for sequential administration, i) being administered first at a dose of 107 pfu to 5×109 pfu and ii) second at a dose of 2 mg/kg to 15 mg/kg.
Dependencies are inferred from the claim text.